Evaluation of the HOXA9 and MEIS1 genes as a potential biomarker in adult acute myeloid leukemia

Background Acute myeloid leukemia (AML) is a heterogeneous disorder encompassing a set of hematopoietic tumors that develop when the myeloid precursor cells undergo disproportionate clonal proliferation. Homeobox A 9 (HOXA9) is a pioneer transcription factor in AML pathogenesis along with its cofact...

Full description

Saved in:
Bibliographic Details
Published in:Egyptian Journal of Medical Human Genetics 2023-12, Vol.24 (1), p.11-11
Main Authors: Abdelrahman, Amira M. N, Tolba, Fetnat Mahmoud, Kamal, Howyda Mohamed, Abdellateif, Mona S, Ahmed, Heba Abdelmoneim, Hassan, Naglaa M
Format: Article
Language:English
Subjects:
Acute myeloid leukemia
Adults
Analysis
Biomarkers
Blood
Bone marrow
Cancer
Cell proliferation
Chemotherapy
Development and progression
Diagnosis
Ethylenediaminetetraacetic acid
Gene expression
Genes
Genetic aspects
Genetic transcription
Hemopoiesis
Homeobox
HOXA9
Kinases
Laboratories
Leukemia
MEIS1
MEIS1 gene
Myelocytic leukemia
Nonlymphoid leukemia
Oncology, Experimental
Patients
Remission (Medicine)
Reverse transcription
RNA
RT-qPCR
Statistical analysis
Survival analysis
Tumors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Acute myeloid leukemia (AML) is a heterogeneous disorder encompassing a set of hematopoietic tumors that develop when the myeloid precursor cells undergo disproportionate clonal proliferation. Homeobox A 9 (HOXA9) is a pioneer transcription factor in AML pathogenesis along with its cofactor myeloid ecotropic integration site 1 (MEIS1). Our work aimed to evaluate the different expression levels of HOXA9 and MEIS1 genes and their diagnostic and prognostic significance in adult Egyptian patients with de novo AML. The study was carried out on 91 de novo AML Egyptian patients and 41 healthy individuals. Bone marrow samples were obtained from both patients and controls and then tested by reverse transcription-quantitative polymerase chain reaction to assess the mRNA expression in the studied genes. Results HOXA9 and MEIS1 gene expression levels were significantly elevated in AML patients compared to controls (p < 0.001). There was a statistically significant positive correlation between HOXA9 and MEIS1 gene expression in AML patients. However, there was no association between HOXA9 and MEIS1 gene expression levels and disease-free survival (DFS) and overall survival (OS) (p = 0.264 and 0.351, respectively). Conclusion HOXA9 and MEIS1 genes are highly expressed in Egyptian AML patients, suggesting their interesting pathogenic role in AML. They could be used as markers for the diagnosis of AML, but not for the disease prognosis.
ISSN:1110-8630
2090-2441
DOI:10.1186/s43042-023-00391-4